IκB-δ Inhibitors

IκB-δ inhibitors, as described above, primarily function by targeting the NF-κB signaling pathway, a key regulator in inflammatory responses, immune system activity, and cell proliferation. The NF-κB pathway involves the phosphorylation and subsequent degradation of IκB proteins, leading to the nuclear translocation of NF-κB and the activation of target genes. Since direct inhibitors of IκB-δ are scarce, these chemicals focus on upstream or parallel components of the NF-κB pathway, thereby influencing IκB-δ activity indirectly. Compounds like BAY 11-7082 and MG-132 target the stability and phosphorylation of IκB proteins, including IκB-δ. By inhibiting IκB-α phosphorylation or proteasome activity, they prevent the degradation of IκB proteins, thus maintaining their inhibitory effect on NF-κB. Other inhibitors, such as IKK-2 Inhibitor IV and IMD-0354, specifically target the IκB kinase (IKK) complex, which is crucial for the phosphorylation of IκB proteins. Inhibition of IKKβ, a component of the IKK complex, leads to decreased IκB phosphorylation and reduced NF-κB activity.

Additionally, compounds like QNZ and Andrographolide inhibit the NF-κB pathway by preventing the nuclear translocation of NF-κB subunits or by modifying key components of the pathway. Sulforaphane and Wedelolactone work by modifying the cysteine residues in the IKK complex, impacting its kinase activity. These inhibitors demonstrate the diverse strategies employed to modulate the NF-κB/IκB-δ axis, ranging from direct kinase inhibition to alterations in protein stability and nuclear translocation processes.